http://www.reutershealth.com/archive/2001/11/01/eline/links/20011101elin038.html
Nov 01, 2001
LONDON, (Reuters Health) - Anti-abortion
campaigners challenging the UK government's embryo cloning regulations
said on Thursday that they were optimistic about a favorable outcome after
a high court judge deferred judgment on the case.
The UK gave the go-ahead to stem
cell and therapeutic cloning research earlier this year, allowing embryos
to be created for this purpose under the 1990 Human Fertilisation and Embryology
Act.
But the ProLife Alliance argues that
cloned embryos cannot be regulated under that Act as they do not fit the
definition of an embryo as stated in the legislation. On Wednesday they
sought a Judicial Review of the parliamentary vote before the High Court,
arguing that the Human Embryology and Fertility Authority cannot licence
the use of the technique.
The government argues that the embryo
definition used in the Act covers both fertilisation and cell nuclear transfer,
or cloning, a spokeswoman for the Department of Health told Reuters Health.
"We are genuinely optimistic," a
spokeswoman for ProLife Alliance told Reuters Health after returning from
court. "We feel the judge absorbed out arguments very quickly." The judge
is expected to come to a decision next week, she said.
"Cloned embryos have not undergone
fertilisation and no sperm are involved in their production; therefore
they are totally outside the regulatory scheme provided by the Act. As
a consequence, the government has no way at present of controlling these
new technologies, leaving us in a very vulnerable position as numerous
rogue scientists press ahead with their plans to clone human beings,''
the group said in a statement.
Therapeutic cloning involves creating
a human embryo from which stem cells--master cells scientists hope will
treat a variety of diseases--can be extracted. The process of extracting
stem cells destroys the embryos a few days after they are created.
The technique of embryo cloning could
allow treatments to be tailored to an individual patient, preventing rejection
of transplanted stem cells. For example, the patient's cells could be used
to create a cloned embryo and then stem cells could be extracted and implanted
back into the patient to treat disease.
Copyright © 2001 Reuters Limited
By Stephen Pincock